JDRF T1D Fund

Any applications received before July 10, 2024 have been archived. If you submitted an application before this date, you need to reapply if you are still interested in being considered for upcoming programs. Upon completion, you will receive a link to update your form as your company grows and evolves. Applications are received on a rolling basis and considered for each month’s featured investor. There is no need to submit new applications or re-apply for specific months.

Calling all early stage biotech, and therapeutic companies; who have interests in, (or who have the capability of) Type 1 Diabetes solutions.

In 2015, a group of JDRF volunteers observed that there was virtually no private investment in curative therapies for T1D, which was causing a gap between scientific advancements and the delivery of solutions to the people who need them.

JDRF’s bold solution was to launch the ‘JDRF T1D Fund’; a venture philanthropy fund to create a market in T1D by using capital and expertise to convince venture capital, biotech and pharma to make the investments needed to cure T1D.

As an independently operating subsidiary of JDRF, the JDRF T1D Fund makes equity investments in biotech companies developing cure-oriented therapies for T1D. Many of the T1D Fund’s investments are companies with existing T1D programs, while others are companies with assets and platforms that have potential to address T1D.